CNBC's UK Exchange newsletter: AstraZeneca gets a shot on Wall Street

GSK announced CEO Emma Walmsley's year-end departure, with Luke Miels named successor, while AstraZeneca (AZ) revealed plans to delist Nasdaq ADRs for a direct NYSE listing of ordinary shares, gaining 0.8% and aiming for broader U.S. investor access. While AZ stressed its continued UK domicile, this move exacerbates concerns over the London Stock Exchange's attractiveness, following a series of high-profile defections by companies like Flutter, Arm, and Ashtead seeking greater U.S. liquidity and potentially higher valuations, often amid frustration with the UK's drug-pricing regime and overall market competitiveness.

Analysis

The UK pharmaceutical landscape is undergoing significant change, highlighted by major announcements from its two largest drugmakers. GSK has announced a leadership transition, with CEO Emma Walmsley departing at year-end to be succeeded by current Chief Commercial Officer Luke Miels, who was notably hired from AstraZeneca eight years prior. Concurrently, AstraZeneca is proceeding with a plan to delist its American Depositary Receipts (ADRs) from the Nasdaq and establish a direct listing of ordinary shares on the New York Stock Exchange. This move, which prompted a 0.8% rise in its share price, is intended to improve liquidity and attract a wider base of U.S. investors, with the potential for future S&P 500 inclusion serving as a key, albeit uncertain, catalyst. While AstraZeneca has emphasized its commitment to maintaining its UK headquarters, tax residency, and primary London listing, the action contributes to a broader, concerning trend of high-profile companies moving their primary listings away from the London Stock Exchange. This exodus includes firms like Flutter, CRH, and Ashtead, often citing the gravity of their North American operations. The context for AstraZeneca's move includes CEO Pascal Soriot's reported frustration with the UK's drug-pricing regime, suggesting this could be a preliminary step toward a full listing transfer if UK policy conditions do not improve. The situation underscores a structural challenge for the London market's competitiveness, with potential remedies like the removal of the 0.5% Stamp Duty Reserve Tax considered unlikely due to fiscal constraints.

Key Decisions for Investors

• For AstraZeneca (AZN), the move to a direct NYSE listing is a positive technical catalyst that should enhance liquidity and expand its U.S. investor base; monitor for developments regarding potential S&P 500 inclusion as this would likely drive further demand.
• The CEO change at GSK introduces leadership uncertainty; investors should closely evaluate incoming CEO Luke Miels' strategic direction, particularly concerning commercial strategy and post-demerger growth drivers.
• The consistent flow of primary listing defections from the London Stock Exchange represents a systemic risk for UK-focused portfolios; it is prudent to assess the 'domicile risk' for UK-listed multinationals with substantial North American revenue, as they may be candidates for a similar move.
• Investors should view any signals from the UK government about removing the 0.5% Stamp Duty Reserve Tax as a significant positive catalyst for the entire UK equity market, as its existence is a noted competitive disadvantage.